ECTRIMS 2022 | New agents under investigation to treat AQP4-positive NMOSD

Kazuo Fujihara, MD, PhD, Fukushima Medical University School of Medicine, Fukushima, Japan, discusses some of the new agents under investigation to treat aquaporin-4-IgG-positive neuromyelitis optica spectrum disorder (AQP4+NMOSD). There are three new monoclonal antibodies under investigation: eculizumab, a terminal complement inhibitor; satralizumab, an anti-interleukin-6 receptor; and inebilizumab, an anti-CD19 agent. The drugs showed positive results in reducing the risk of relapse in AQP4+NMOSD patients and have since been approved in some countries, such as the USA, but not in others. This is because the long-term safety and efficacy of these drugs are currently being collected through open-label extension trials. This interview took place at the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) Congress 2022 in Amsterdam, The Netherlands.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.